These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 9472847)

  • 21. Methodology, results and quality of clinical trials of tacrine in the treatment of Alzheimer's disease: a systematic review of the literature.
    Arrieta JL; Artalejo FR
    Age Ageing; 1998 Mar; 27(2):161-79. PubMed ID: 16296676
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aminotransferase levels and silymarin in de novo tacrine-treated patients with Alzheimer's disease.
    Allain H; Schück S; Lebreton S; Strenge-Hesse A; Braun W; Gandon JM; Brissot P
    Dement Geriatr Cogn Disord; 1999; 10(3):181-5. PubMed ID: 10325444
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Somatostatin and cognitive functions in Alzheimer's disease--the relationship of cerebrospinal fluid somatostatin increase with clinical response to tetrahydroaminoacridine.
    Alhainen K; Sirviö J; Helkala EL; Reinikainen K; Riekkinen P
    Neurosci Lett; 1991 Sep; 130(1):46-8. PubMed ID: 1684233
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Maximizing function in Alzheimer's disease: what role for tacrine?
    Smucker WD
    Am Fam Physician; 1996 Aug; 54(2):645-52. PubMed ID: 8701842
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Convulsive crisis as a possible adverse reaction to the treatment with tacrine in Alzheimer's disease].
    García-Díaz JD; Fraguas C; Garcimartín C
    Med Clin (Barc); 1998 Sep; 111(7):279. PubMed ID: 9789247
    [No Abstract]   [Full Text] [Related]  

  • 26. Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. Groupe Français d'Etude de la Tetrahydroaminoacridine.
    Chatellier G; Lacomblez L
    BMJ; 1990 Feb; 300(6723):495-9. PubMed ID: 2107926
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit.
    Giacobini E; Spiegel R; Enz A; Veroff AE; Cutler NR
    J Neural Transm (Vienna); 2002 Jul; 109(7-8):1053-65. PubMed ID: 12111443
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term tacrine treatment in three mild Alzheimer patients: effects on nicotinic receptors, cerebral blood flow, glucose metabolism, EEG, and cognitive abilities.
    Nordberg A; Amberla K; Shigeta M; Lundqvist H; Viitanen M; Hellström-Lindahl E; Johansson M; Andersson J; Hartvig P; Lilja A; Långström B; Winblad B
    Alzheimer Dis Assoc Disord; 1998 Sep; 12(3):228-37. PubMed ID: 9772028
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cerebral glucose metabolism, cerebrospinal fluid-beta-amyloid1-42 (CSF-Abeta42), tau and apolipoprotein E genotype in long-term rivastigmine and tacrine treated Alzheimer disease (AD) patients.
    Stefanova E; Blennow K; Almkvist O; Hellström-Lindahl E; Nordberg A
    Neurosci Lett; 2003 Feb; 338(2):159-63. PubMed ID: 12566177
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Variability in the plasma protein binding of velnacrine (1-hydroxy tacrine hydrochloride). A potential agent for Alzheimer's disease.
    Wood DM; Ford JM; Roberts CJ
    Eur J Clin Pharmacol; 1996; 50(1-2):115-9. PubMed ID: 8739821
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tolerance to tacrine, arterial hypotension and leuko-araiosis in Alzheimer's disease.
    Lebert F; Mouly C; Pasquier F
    Age Ageing; 1998 Sep; 27(5):654. PubMed ID: 12675108
    [No Abstract]   [Full Text] [Related]  

  • 32. The caffeine breath test does not identify patients susceptible to tacrine hepatotoxicity.
    Fontana RJ; Turgeon DK; Woolf TF; Knapp MJ; Foster NL; Watkins PB
    Hepatology; 1996 Jun; 23(6):1429-35. PubMed ID: 8675160
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mixed-model analysis of incomplete longitudinal data from a high-dose trial of tacrine (Cognex) in Alzheimer's patients.
    Smith F
    J Biopharm Stat; 1996 Mar; 6(1):59-67. PubMed ID: 8838779
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Therapeutic results: tacrine].
    Ventura M; Sternon J
    Rev Med Brux; 1997 Dec; 18(6):394-7. PubMed ID: 9481161
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Caffeine based measures of CYP1A2 activity correlate with oral clearance of tacrine in patients with Alzheimer's disease.
    Fontana RJ; deVries TM; Woolf TF; Knapp MJ; Brown AS; Kaminsky LS; Tang BK; Foster NL; Brown RR; Watkins PB
    Br J Clin Pharmacol; 1998 Sep; 46(3):221-8. PubMed ID: 9764962
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Guidelines for the use of tacrine in Alzheimer's disease: clinical application and effectiveness. Johns Hopkins Dementia Research Clinic.
    Lyketsos CG; Corazzini K; Steele CD; Kraus MF
    J Neuropsychiatry Clin Neurosci; 1996; 8(1):67-73. PubMed ID: 8845704
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tacrine: first drug approved for Alzheimer's disease.
    Crismon ML
    Ann Pharmacother; 1994 Jun; 28(6):744-51. PubMed ID: 7919566
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Velnacrine for the treatment of Alzheimer's disease: a double-blind, placebo-controlled trial. The Mentane Study Group.
    Zemlan FP
    J Neural Transm (Vienna); 1996; 103(8-9):1105-16. PubMed ID: 9013398
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of bis(7)-tacrine, a novel anti-Alzheimer's agent, on rat brain AChE.
    Wang H; Carlier PR; Ho WL; Wu DC; Lee NT; Li CP; Pang YP; Han YF
    Neuroreport; 1999 Mar; 10(4):789-93. PubMed ID: 10208549
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group.
    Knapp MJ; Knopman DS; Solomon PR; Pendlebury WW; Davis CS; Gracon SI
    JAMA; 1994 Apr; 271(13):985-91. PubMed ID: 8139083
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.